Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 959
Rating:

Dr Edward B. Garon - UCLA, Los Angeles, USA

Dr Edward B. Garon talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of immunotherapy agent pembrolizumab as treatment for advanced non-small cell lung cancer.

He explains that this phase Ib study is an update from the original trial updating the non-small cell lung cancer.

Dr Garon reports that after the 5 year point 15% of patients are alive, particularly those who had a high sustaining for PD-L1 (a quarter of these patients).

​Watch the press conference here.

Watch a comment from Dr David Graham here

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation